BioTrinity 2014 counted 130+ investment delegates from 12 countries, significantly up again on the previous year. We are delighted that corporate venture fund involvement at BioTrinity has continued to grow!  The new trend continues: a number of investor firms are sending more than one delegate, increasing the chance of you getting that all important meeting.  This year again, we actively monitor the quality of investment firms which we allow to participate, which we continue to improve year-on-year.  A significant number of Business Angels specializing in life sciences are attending, but to protect their privacy they are not automatically listed below. The vast majority of those listed below are already registered, with the remainder having confirmed they will attend.  This page is updated weekly or more frequently, so come back regularly to see which new investors sign up to attend.

Investment Firms who participated in 2014:

  • AbbVie, Inc (USA)
  • Abingworth (UK)
  • Advent Venture Partners (UK)
  • Akesios Associates (UK)
  • Albion Ventures LLP (UK)
  • Andy Richards (UK)
  • Angel Capital Group (UK)
  • Apposite Capital (UK)
  • Arthurian Life Sciences (UK)
  • Auriga Partners (France)
  • Bay City Capital (US)
  • Beringea LLP (UK)
  • Bluelane Capital (USA)
  • Boehringer Ingelheim Venture Fund GmbH (Germany)
  • Cambridge Angels - Various (UK)
  • Cambridge Innovation Capital plc (UK)
  • Clubb Capital (UK)
  • Delta Partners (Ireland)
  • DFJ Esprit (UK)
  • ECI Partners (UK)
  • Edmond de Rothschild Investment Partners (France)
  • Entrepreneurs Fund (UK)
  • Epidarex Capital (UK)
  • Esperante (Netherlands)
  • Fidelity Biosciences (UK)
  • Finance Wales (UK)
  • Forbion Capital Partners (Netherlands)
  • Fountain Healthcare Partners (Ireland)
  • GHO Capital (UK)
  • Gilde Healthcare Partners (Netherlands)
  • Harbert European Growth Capital Fund (UK)
  • HNW Family Fund (UK)
  • Imperial Innovations (UK)
  • Index Ventures (UK)
  • Inventages Venture Capital (UK)
  • Invesco Perpetual (UK)
  • IP Group plc (UK)
  • IPF Partners (Luxembourg)
  • J&J Dev Corp (USA)
  • Kreos Capital (UK)
  • London Business Angels - Various (UK)
  • Longwall Ventures (UK)
  • LSP Health Economics Fund (Belgium)
  • Lundbeckfond Ventures (Denmark)
  • Mann BioInvest (UK)
  • MedImmune Ventures (USA)
  • Mercia Fund Management (UK)
  • Mérieux Developpement (France)
  • MRL Venture Fund (USA)
  • Midven (UK)
  • Mitsui & Co Global Investment (USA)
  • MP Healthcare Venture Management (USA)
  • MS Ventures (Switzerland)
  • MVM Life Science Partners (UK)
  • NGBI Ventures (UK)
  • NeoMed (Switzerland)
  • NetScientific plc (UK)
  • New Enterprise Associates (USA)
  • New Hill Management (UK)
  • Norgine Ventures Investment (UK)
  • Novartis Venture Funds (Switzerland)
  • Novo A/S (Denmark)
  • Novo Nordisk (Denmark)
  • Novo Seeds (Denmark)
  • O2H Ventures (UK)
  • Oriel Securities (UK)
  • Oxford Capital (UK)
  • Oxford Finance (USA)
  • Oxford Spin-out Equity Management (UK)
  • Oxford Technology (UK)
  • Peel Hunt (UK)
  • Phase4 Partners (UK)
  • Rosetta Capital (UK)
  • SEP (UK)
  • Seroba Kernel (Ireland)
  • Seventure Partners (France)
  • Silicon Valley Bank (UK)
  • Sixth Element Capital (UK)
  • Sofinnova Partners (France)
  • Sofinnova Ventures (Ireland)
  • SPARK Impact (UK)
  • SR One (UK)
  • SV Life Sciences (UK)
  • Syncona Partners (UK)
  • Synergis Technologies (UK)
  • Takeda Ventures (USA)
  • Technology Strategy Board (UK)
  • The Summit Group (UK)
  • TVM Capital (Germany)
  • Unilever Ventures (UK)
  • venBIO LLC (USA)
  • Ventac Partners (Spain)
  • Visium Asset Management (UK)
  • Wellcome Trust (UK)
  • Wellington Parnters (Germany)
  • Wombat Capital (USA)
  • Wren Capital (UK)
  • Yorkville Advisors (USA)
  • Ysios Capital (Spain)
  • Zoetis (US)

See the list of previous years' investors





BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
80 global pharma/corporate venture delegates
33 global pharma/medical technology corporates